抗血小板因子4抗體(Anti-PF4)檢測試劑盒(酶聯(lián)免疫吸附試驗法)
ELISA Kit for Anti-Platelet Factor 4 Antibody (Anti-PF4)
CXCL4; SCYB4; Chemokine C-X-C-Motif Ligand 4; Oncostatin-A; Iroplact
- 編號UAEA172Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實驗方法間接法
- 反應(yīng)時長2h, 30min
- 檢測范圍3.12-200ng/mL
- 靈敏度最小可檢測劑量小于等于1.27ng/mL.
- 樣本類型serum, plasma and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價格 ¥ 1890 ¥ 2700 ¥ 12150 ¥ 22950 ¥ 189000
- 欲了解實際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實驗結(jié)果圖
-
標準曲線圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
特異性
本試劑盒用于檢測抗血小板因子4抗體(Anti-PF4)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的抗血小板因子4抗體(Anti-PF4)（加標樣品），重復(fù)測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 84-98 | 94 |
| EDTA plasma(n=5) | 96-105 | 101 |
| heparin plasma(n=5) | 88-101 | 93 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進行定量檢測,每份樣本連續(xù)測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的抗血小板因子4抗體(Anti-PF4)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中抗血小板因子4抗體(Anti-PF4)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 79-101% | 97-105% | 94-101% | 84-98% |
| EDTA plasma(n=5) | 95-104% | 88-97% | 78-103% | 98-105% |
| heparin plasma(n=5) | 83-103% | 92-99% | 91-98% | 96-105% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實驗室的環(huán)境條件需盡量保持一致，尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進行操作可減少人為誤差。
實驗流程
1. 實驗前標準品、試劑及樣本的準備；
2. 加樣（標準品及樣本）100µL，37°C孵育1小時；
3. 吸棄，加檢測溶液A100μL，37°C孵育1小時；
4. 洗板5次；
5. 加TMB底物90µL，37°C孵育10-20分鐘；
6. 加終止液50µL，立即450nm讀數(shù)。
實驗原理
將抗原包被于96孔微孔板中，制成固相載體，向微孔中分別加入標準品或標本，其中的抗血小板因子4抗體(Anti-PF4)與連接于固相載體上的抗原結(jié)合，然后加入HRP標記的二抗，徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的抗血小板因子4抗體(Anti-PF4)呈正相關(guān)。用酶標儀在450nm波長下測定吸光度(O.D.值)，計算樣品濃度。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| UAPA172Hu01 | 血小板因子4(PF4)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPA172Hu01 | 血小板因子4(PF4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA172Hu02 | 血小板因子4(PF4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA172Hu01 | 血小板因子4(PF4)多克隆抗體 | IHC |
| UPAA172Hu02 | 血小板因子4(PF4)多克隆抗體 | WB |
| ULAA172Hu71 | 血小板因子4(PF4)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| ULAA172Hu81 | 血小板因子4(PF4)多克隆抗體(異硫氰酸熒光素標記) | WB; IHC; ICC; IF. |
| UMAA172Hu21 | 血小板因子4(PF4)單克隆抗體 | ICC/IF |
| UMAA172Hu23 | 血小板因子4(PF4)單克隆抗體 | IHC |
| UMAA172Hu24 | 血小板因子4(PF4)單克隆抗體 | WB; ICC/IF |
| UMAA172Hu22 | 血小板因子4(PF4)單克隆抗體 | WB; IHC |
| UMAA172Hu25 | 血小板因子4(PF4)單克隆抗體 | ICC/IF |
| USEA172Hu | 血小板因子4(PF4)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| UAEA172Hu | 抗血小板因子4抗體(Anti-PF4)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
| USCA172Hu | 血小板因子4(PF4)檢測試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| ULMA172Hu | 血小板因子4(PF4)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UPSA172Hu01 | 血小板因子4(PF4)抗體對 | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
| UKSA172Hu01 | 血小板因子4(PF4)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻
| 雜志 | 參考文獻 |
| Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics | Propofol lowers serum PF4 level and partially corrects hypercoagulopathy in endotoxemic rats [PubMed: 20601223] |
| Basic Research in Cardiology | Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilation [PubMed: 22899170] |
| PLoS One | Platelets Recognize Brain-Specific Glycolipid Structures, Respond to Neurovascular Damage and Promote Neuroinflammation [PubMed: PMC3608633] |
| Diving and Hyperbaric Medicine | Effect of splenectomy on platelet activation and decompression sickness outcome in a rat model of decompression [Pubmed:25311322] |
| Journal of Functional Foods | A?Phellinus baumii–based supplement containing?Salvia miltiorrhiza?Bunge improves atherothrombotic profiles through endothelial nitric oxide synthase and cyclooxygenase pathwaysin vitro?and?in vivo [science:S1756464616300676] |
| Plos one | Aspirin, but Not Tirofiban Displays Protective Effects in Endotoxin Induced Lung Injury [pubmed:27583400] |
| international journal of molecular sciences | Evidence of the Role of R-Spondin 1 and Its Receptor Lgr4 in the Transmission of Mechanical Stimuli to Biological Signals for Bone Formation. [pubmed:28272338] |
| Experimental?and?Therapeutic?Medicine | Feasibility of improving platelet?rich plasma therapy by using chitosan with high platelet activation ability [pubmed:28450960] |
| Reproductive Toxicology | Aspirin pre-treatment modulates ozone-induced fetal growth restriction and alterations in uterine blood flow in rats [Pubmed: 30528429] |
| INTERNATIONAL JOURNAL OF CARDIOLOGY | Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablation [Pubmed: 30857843] |
| Available at SSRN 3335365? | Evaluating the Platelet Activation Related to the Degradation of Biomaterials by Scheme of Molecular Markers [] |
| journal of biotechnology | Newly Identified HNP‐F from Human Neutrophil Peptide 1 Promotes Hemostasis [Pubmed: 30927490] |
| Data in Brief | Data for short and long-term prothrombotic biomarkers after cryoballoon and radiofrequency ablation [] |
| journal of thoracic and cardiovascular surgery | Evaluating Platelet Activation Related to the Degradation of Biomaterials Using Molecular Markers [Pubmed: 32812629] |
| Marine Drugs | The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents [Pubmed: 31533230] |
| Thrombosis Research | Feasibility study of use of rabbit blood to evaluate platelet activation by medical devices [Pubmed: 31838449] |
| Nat Commun | The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets [34099640] |
| Vaccine | The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats [Pubmed:35183388] |
